Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rhesus Negative Obstetric Population in Western Australia Receiving Treatment for the Prevention of Sensitisation to the D-Antigen: Comparison of Existing Australian Dosing Regime and a Single 1500IU Dose to Assess Protection from Sensitisation and Patient Compliance

Trial Profile

Rhesus Negative Obstetric Population in Western Australia Receiving Treatment for the Prevention of Sensitisation to the D-Antigen: Comparison of Existing Australian Dosing Regime and a Single 1500IU Dose to Assess Protection from Sensitisation and Patient Compliance

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-D Rh0 immunoglobulin (Primary)
  • Indications Haemolytic disease of newborn; Pregnancy complications
  • Focus Therapeutic Use
  • Acronyms DACTR

Most Recent Events

  • 20 Apr 2017 Status changed from recruiting to completed.
  • 26 Aug 2013 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top